|
The 3rd Abu Dhabi Advanced Rheumatology Review Course (ADARRC) brings more than 350 global experts in bone and joint diseases to the capital to present and share their valuable clinical knowledge and their latest basic and clinical research findings. Health Authority-Abu Dhabi (HAAD) has accredited ADARRC for Continuing Medical Education (CME) and has awarded the program 23.75 CME hours.
Organised by Mafraq Hospital, which is owned and operated by the Abu Dhabi Health Services Company PJSC (SEHA); SEHA and Abu Dhabi Convention Bureau; the review course will run until 30 September (Monday) at Fairmont Bab Al Bahr Hotel, Abu Dhabi.
The three-day scientific and educational meeting is designed to keep delegates abreast of developments in the fields of rheumatology and clinical immunology. It covers multiple selected topics in experimental innovative therapies presented by international and regional key opinion leaders in Rheumatology.
Dr Mustafa Al-Maini, MD, Msc FRCPC, Chief of Rheumatology, Allergy and Clinical Immunology Division at Mafraq Hospital, is leading the efforts to organize the event, following its huge success since inception in 2011. Dr Al-Maini said, “We have received encouraging response from global experts who are keen to evaluate new and future treatment approaches, share their expertise and determine the most effective technologies for joint and bones diseases.
“We are particularly thankful to the supporters of the event who recognize the importance of ADARRC in spreading awareness for proper diagnosis and treatment of the rheumatoid arthritis that affects 20% of the population of the UAE.”
The event is supported by Mafraq Hospital, owned and operated by the Abu Dhabi Health Services Company PJSC (SEHA); SEHA and Abu Dhabi Convention Bureau. Key sponsors include Pfizer, Abbott Laboratories, Bristol-Myers Squibb, Roche, Janssen and NewBridge Pharmaceuticals. For more information about the event, please visit www.rheumatology.ae.
|
New
Review
Abu Dhabi International Airport - 41°F
